우리 Fcst 채점판 — 맞혔는가, 직전 분기 유지보다 나았는가Our Fcst scorecard — did it hit, and did it beat carrying the previous quarter forward?当サイトFcst採点表 — 当たったか、前四半期据え置きより良かったか
이 사이트가 내놓는 모든 '우리 Fcst'(Adrenalin Baby Fcst, 컨센서스 아님)를 한곳에 모아 채점한다. 전진 검증은 그 분기 전 자료로만 맞추고 그 분기를 맞힌 오차이고, 기준선은 직전 분기 값을 그대로 둔 것이다. 지금 열린 예측은 첫 발행값과 마지막 발행값을 Raw Data 에 박아 두고 실제가 나오면 둘 다 채점한다. 기준선을 못 이긴 모델은 예측을 내지 않고 그 사실을 적는다.Every 'our Fcst' this site issues (Adrenalin Baby Fcst, not consensus) is gathered and scored in one place. The forward test is the error of a forecast fitted only on data from before the quarter and then scored against that quarter; the baseline simply carries the previous quarter's value forward. For forecasts still open, the first and the latest issued values are fixed in the Raw Data and both are scored once the actual comes out. A model that fails to beat the baseline issues no forecast, and that fact is recorded.当サイトが出すすべての「当サイトFcst」(Adrenalin Baby Fcst、コンセンサスではない)を一か所に集めて採点する。フォワードテストは、その四半期より前のデータだけで当てはめてその四半期を当てたときの誤差であり、基準線は前四半期の値をそのまま据え置いたものだ。未決着の予測は初回発行値と最終発行値をRaw Dataに固定し、実績が出れば両方を採点する。基準線に勝てなかったモデルは予測を出さず、その事実を記す。
먼저 보는 세 줄Three lines firstまず見る三行
Created 2026-11-01- 전진 검증 89분기 중 55분기에서 직전 분기 유지보다 가까웠다 — 모델 6개 중 과반·평균 둘 다 이긴 것 4개, 우연과 구분되는 것(p ≤ 0.05) 1개.Of 89 forward-test quarters, 55 came closer than the previous quarter carried forward — of 6 models, 4 beat it on both the majority and the mean, and 1 can be told apart from chance (p ≤ 0.05).フォワードテスト89四半期のうち55四半期で前四半期据え置きより近かった — モデル6個のうち過半・平均の両方で勝ったものが4個、偶然と区別できるもの(p ≤ 0.05)が1個。
- 지금 열려 있는 Fcst 25건 — 실제가 나오면 첫 발행값과 마지막 발행값을 둘 다 채점한다. 채점 끝난 건 0건(이김 0).25 Fcst are open now — once the actual comes out, both the first and the latest issued values are scored. Scored so far: 0 (won 0).現在未決着のFcstは25件 — 実績が出れば初回発行値と最終発行値の両方を採点する。採点済みは0件(勝ち0)。
- 기준선을 못 이긴 모델은 Fcst 를 내지 않고 그 사실을 적는다(셀트리온). 선행 P/E 나우캐스트는 3Q26 보고서가 모이면 합류한다.기준선을 못 이긴 모델은 Fcst 를 내지 않고 그 사실을 적는다(셀트리온). 선행 P/E 나우캐스트는 3Q26 보고서가 모이면 합류한다.기준선을 못 이긴 모델은 Fcst 를 내지 않고 그 사실을 적는다(셀트리온). 선행 P/E 나우캐스트는 3Q26 보고서가 모이면 합류한다.
삼성바이오로직스 분기 매출Samsung Biologics quarterly revenueSamsung Biologics 四半期売上高 기준선과 구분 안 됨not distinguishable from the baseline基準線と区別できない
%%% · Data as of 2026-09 · Created 2026-11-01드라이버: 관세청 원료 수출(한·두 분기 앞 평균). 전진 검증 7분기 — 평균 |오차| 6.03% vs 직전 분기 유지 6.6% · 이긴 분기 3/7 · 우연으로 그만큼 이길 확률 0.77. 판정: 기준선과 구분되지 않는다. 자세한 모델은 그 페이지에.Driver: Korea biologic drug-substance exports (customs), one and two quarters ahead. Forward test over 7 quarters — mean |error| 6.03% vs 6.6% for the previous quarter carried forward · quarters won 3/7 · probability of winning that many by chance 0.77. Verdict: not distinguishable from the baseline. The full model is on its page.ドライバー: 関税庁の原薬輸出(1・2四半期先の平均)。フォワードテスト7四半期 — 平均|誤差| 6.03%(前四半期据え置きは6.6%)· 勝った四半期 3/7 · 偶然でそれだけ勝つ確率 0.77。判定: 基準線と区別できない。モデルの詳細はそのページに。
| 분기Quarter四半期 | 예측Forecast (KRW 100mn)予測(億ウォン) | 실제Actual (KRW 100mn)実績(億ウォン) | 직전 분기 유지Previous quarter carried forward (KRW 100mn)前四半期据え置き(億ウォン) | 모델 오차Model errorモデル誤差 | 기준선 오차Baseline error基準線誤差 | 판정Verdict判定 |
|---|---|---|---|---|---|---|
| 2025Q1 | 8,964억 | 9,995억 | 9,504억 | -10.3%%% | -4.9%%% | 짐lost負け |
| 2025Q2 | 11,213억 | 10,142억 | 9,995억 | +10.6%%% | -1.4%%% | 짐lost負け |
| 2025Q3 | 12,399억 | 12,575억 | 10,142억 | -1.4%%% | -19.3%%% | 이김won勝ち |
| 2025Q4 | 12,174억 | 12,857억 | 12,575억 | -5.3%%% | -2.2%%% | 짐lost負け |
| 2026Q1 | 12,992억 | 12,571억 | 12,857억 | +3.3%%% | +2.3%%% | 짐lost負け |
| 2026Q2 | 13,724억 | 13,209억 | 12,571억 | +3.9%%% | -4.8%%% | 이김won勝ち |
| 2026Q3 | 16,001억 | 14,903억 | 13,209억 | +7.4%%% | -11.4%%% | 이김won勝ち |
| 열린 Fcst · 분기Open Fcst · quarter未決着のFcst · 四半期 | 첫 발행First issued初回発行 | 첫 값First value (KRW 100mn)初回値(億ウォン) | 마지막 발행Latest issued最終発行 | 마지막 값Latest value (KRW 100mn)最終値(億ウォン) | 직전 분기 유지Previous quarter carried forward (KRW 100mn)前四半期据え置き(億ウォン) | ± | 실제Actual実績 | 상태Status状態 |
|---|---|---|---|---|---|---|---|---|
| 2026Q4 | 2026-10-22 | 14,576억 | 2026-10-22 | 14,576억 | 14,903억 | 6.0% | 대기 · 마감 2027-03-31pending · due 2027-03-31待機 · 期限 2027-03-31 | 열림open未決着 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
셀트리온 분기 매출Celltrion quarterly revenueCelltrion 四半期売上高 기준선과 구분 안 됨not distinguishable from the baseline基準線と区別できないFcst 미발행Fcst not issuedFcst未発行
%%% · Data as of 2026-09 · Created 2026-11-01드라이버: 관세청 완제 수출 · 헝가리행(전 분기). 전진 검증 6분기 — 평균 |오차| 13.14% vs 직전 분기 유지 14.5% · 이긴 분기 3/6 · 우연으로 그만큼 이길 확률 0.66. 판정: 기준선과 구분되지 않는다. 전진 검증에서 직전 분기 유지를 과반 분기에서 못 이겨 Fcst 를 내지 않는다. 자세한 모델은 그 페이지에.Driver: Korea dose-form immunological exports, Hungary-bound (customs), prior quarter. Forward test over 6 quarters — mean |error| 13.14% vs 14.5% for the previous quarter carried forward · quarters won 3/6 · probability of winning that many by chance 0.66. Verdict: not distinguishable from the baseline. In the forward test it did not beat the previous quarter carried forward in a majority of quarters, so no Fcst is issued. The full model is on its page.ドライバー: 関税庁の完成品輸出 · ハンガリー向け(前四半期)。フォワードテスト6四半期 — 平均|誤差| 13.14%(前四半期据え置きは14.5%)· 勝った四半期 3/6 · 偶然でそれだけ勝つ確率 0.66。判定: 基準線と区別できない。フォワードテストで過半の四半期において前四半期据え置きに勝てなかったため、Fcstを出さない。モデルの詳細はそのページに。
| 분기Quarter四半期 | 예측Forecast (KRW 100mn)予測(億ウォン) | 실제Actual (KRW 100mn)実績(億ウォン) | 직전 분기 유지Previous quarter carried forward (KRW 100mn)前四半期据え置き(億ウォン) | 모델 오차Model errorモデル誤差 | 기준선 오차Baseline error基準線誤差 | 판정Verdict判定 |
|---|---|---|---|---|---|---|
| 2025Q2 | 8,759억 | 9,615억 | 8,419억 | -8.9%%% | -12.4%%% | 이김won勝ち |
| 2025Q3 | 8,735억 | 10,290억 | 9,615억 | -15.1%%% | -6.6%%% | 짐lost負け |
| 2025Q4 | 9,576억 | 13,302억 | 10,290억 | -28.0%%% | -22.6%%% | 짐lost負け |
| 2026Q1 | 11,614억 | 11,450억 | 13,302억 | +1.4%%% | +16.2%%% | 이김won勝ち |
| 2026Q2 | 12,710억 | 13,937억 | 11,450억 | -8.8%%% | -17.8%%% | 이김won勝ち |
| 2026Q3 | 13,142억 | 15,755억 | 13,937억 | -16.6%%% | -11.5%%% | 짐lost負け |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
LG화학 분기 영업이익률(LG엔솔 제외)LG Chem quarterly operating margin (ex LG Energy Solution)LG Chem 四半期営業利益率(LG Energy Solution除く) 기준선 이김beats the baseline基準線に勝利
%ppp%pt · Data as of 2026Q2 · Created 2026-11-01드라이버: 관세청 제품·원료 단가 스프레드 + 브렌트 다리. 전진 검증 10분기 — 평균 |오차| 2.20%p vs 직전 분기 유지 3.46%p · 이긴 분기 7/10 · 우연으로 그만큼 이길 확률 0.17. 판정: 기준선보다 낫다(과반·평균 모두). 자세한 모델은 그 페이지에.Driver: customs product/raw-material unit prices with a Brent bridge (M2). Forward test over 10 quarters — mean |error| 2.20pp vs 3.46pp for the previous quarter carried forward · quarters won 7/10 · probability of winning that many by chance 0.17. Verdict: better than the baseline (on both the majority and the mean). The full model is on its page.ドライバー: 関税庁の製品・原料単価スプレッド + ブレントのブリッジ。フォワードテスト10四半期 — 平均|誤差| 2.20%pt(前四半期据え置きは3.46%pt)· 勝った四半期 7/10 · 偶然でそれだけ勝つ確率 0.17。判定: 基準線より良い(過半・平均の両方)。モデルの詳細はそのページに。
| 분기Quarter四半期 | 예측Forecast予測 | 실제Actual実績 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | 모델 오차Model errorモデル誤差 | 기준선 오차Baseline error基準線誤差 | 판정Verdict判定 |
|---|---|---|---|---|---|---|
| 2024Q1 | -0.3% | 2.0% | -1.6% | -2.27%ppp%pt | -3.57%ppp%pt | 이김won勝ち |
| 2024Q2 | 5.9% | 3.4% | 2.0% | +2.51%ppp%pt | -1.47%ppp%pt | 짐lost負け |
| 2024Q3 | 2.6% | 0.9% | 3.4% | +1.69%ppp%pt | +2.57%ppp%pt | 이김won勝ち |
| 2024Q4 | 1.7% | -0.5% | 0.9% | +2.16%ppp%pt | +1.32%ppp%pt | 짐lost負け |
| 2025Q1 | 2.3% | 1.2% | -0.5% | +1.12%ppp%pt | -1.67%ppp%pt | 이김won勝ち |
| 2025Q2 | 3.0% | -0.3% | 1.2% | +3.23%ppp%pt | +1.49%ppp%pt | 짐lost負け |
| 2025Q3 | 0.6% | 1.4% | -0.3% | -0.80%ppp%pt | -1.69%ppp%pt | 이김won勝ち |
| 2025Q4 | -1.1% | -6.0% | 1.4% | +4.92%ppp%pt | +7.43%ppp%pt | 이김won勝ち |
| 2026Q1 | -0.3% | 2.8% | -6.0% | -3.12%ppp%pt | -8.78%ppp%pt | 이김won勝ち |
| 2026Q2 | 7.2% | 7.4% | 2.8% | -0.18%ppp%pt | -4.57%ppp%pt | 이김won勝ち |
| 열린 Fcst · 분기Open Fcst · quarter未決着のFcst · 四半期 | 첫 발행First issued初回発行 | 첫 값First value初回値 | 마지막 발행Latest issued最終発行 | 마지막 값Latest value最終値 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | ± | 실제Actual実績 | 상태Status状態 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-10-22 | 2.3% | 2026-10-22 | 2.3% | 7.4% | 2.2%ppp%pt | 대기 · 마감 2026-11-14pending · due 2026-11-14待機 · 期限 2026-11-14 | 열림open未決着 |
| 2026Q4 | 2026-10-22 | -0.9% | 2026-10-23 (2회) (2 issues)(2回) | -0.7% | 7.4% | 2.2%ppp%pt | 대기 · 마감 2027-03-31pending · due 2027-03-31待機 · 期限 2027-03-31 | 열림open未決着 |
| 2027Q1 | 2026-10-22 | -1.2% | 2026-10-23 (2회) (2 issues)(2回) | -1.0% | 7.4% | 2.2%ppp%pt | 대기 · 마감 2027-05-15pending · due 2027-05-15待機 · 期限 2027-05-15 | 열림open未決着 |
| 2027Q2 | 2026-10-22 | -1.2% | 2026-10-23 (2회) (2 issues)(2回) | -1.0% | 7.4% | 2.2%ppp%pt | 대기 · 마감 2027-08-14pending · due 2027-08-14待機 · 期限 2027-08-14 | 열림open未決着 |
| 2027Q3 | 2026-10-22 | -1.2% | 2026-10-23 (2회) (2 issues)(2回) | -1.0% | 7.4% | 2.2%ppp%pt | 대기 · 마감 2027-11-14pending · due 2027-11-14待機 · 期限 2027-11-14 | 열림open未決着 |
| 2027Q4 | 2026-10-22 | -1.2% | 2026-10-23 (2회) (2 issues)(2回) | -1.0% | 7.4% | 2.2%ppp%pt | 대기 · 마감 2028-03-30pending · due 2028-03-30待機 · 期限 2028-03-30 | 열림open未決着 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
금호석유화학 분기 영업이익률Kumho Petrochemical quarterly operating marginKumho Petrochemical 四半期営業利益率 기준선 이김beats the baseline基準線に勝利
%ppp%pt · Data as of 2026Q2 · Created 2026-11-01드라이버: 관세청 제품·원료 단가 스프레드 + 브렌트 다리. 전진 검증 30분기 — 평균 |오차| 3.76%p vs 직전 분기 유지 4.11%p · 이긴 분기 17/30 · 우연으로 그만큼 이길 확률 0.29. 판정: 기준선보다 낫다(과반·평균 모두). 자세한 모델은 그 페이지에.Driver: customs product/raw-material unit prices with a Brent bridge (C2). Forward test over 30 quarters — mean |error| 3.76pp vs 4.11pp for the previous quarter carried forward · quarters won 17/30 · probability of winning that many by chance 0.29. Verdict: better than the baseline (on both the majority and the mean). The full model is on its page.ドライバー: 関税庁の製品・原料単価スプレッド + ブレントのブリッジ。フォワードテスト30四半期 — 平均|誤差| 3.76%pt(前四半期据え置きは4.11%pt)· 勝った四半期 17/30 · 偶然でそれだけ勝つ確率 0.29。判定: 基準線より良い(過半・平均の両方)。モデルの詳細はそのページに。
| 분기Quarter四半期 | 예측Forecast予測 | 실제Actual実績 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | 모델 오차Model errorモデル誤差 | 기준선 오차Baseline error基準線誤差 | 판정Verdict判定 |
|---|---|---|---|---|---|---|
| 2019Q1 | 6.5% | 11.3% | 6.2% | -4.84%ppp%pt | -5.08%ppp%pt | 이김won勝ち |
| 2019Q2 | 9.9% | 10.7% | 11.3% | -0.78%ppp%pt | +0.60%ppp%pt | 짐lost負け |
| 2019Q3 | 9.3% | 5.6% | 10.7% | +3.64%ppp%pt | +5.08%ppp%pt | 이김won勝ち |
| 2019Q4 | 6.2% | 1.3% | 5.6% | +4.84%ppp%pt | +4.29%ppp%pt | 짐lost負け |
| 2020Q1 | 4.3% | 10.9% | 1.3% | -6.55%ppp%pt | -9.52%ppp%pt | 이김won勝ち |
| 2020Q2 | 9.0% | 11.7% | 10.9% | -2.70%ppp%pt | -0.84%ppp%pt | 짐lost負け |
| 2020Q3 | 11.9% | 18.0% | 11.7% | -6.05%ppp%pt | -6.28%ppp%pt | 이김won勝ち |
| 2020Q4 | 24.1% | 20.1% | 18.0% | +4.05%ppp%pt | -2.10%ppp%pt | 짐lost負け |
| 2021Q1 | 20.2% | 33.0% | 20.1% | -12.78%ppp%pt | -12.94%ppp%pt | 이김won勝ち |
| 2021Q2 | 29.9% | 34.3% | 33.0% | -4.37%ppp%pt | -1.24%ppp%pt | 짐lost負け |
| 2021Q3 | 28.3% | 28.0% | 34.3% | +0.32%ppp%pt | +6.31%ppp%pt | 이김won勝ち |
| 2021Q4 | 24.9% | 19.1% | 28.0% | +5.81%ppp%pt | +8.84%ppp%pt | 이김won勝ち |
| 2022Q1 | 19.8% | 20.4% | 19.1% | -0.61%ppp%pt | -1.30%ppp%pt | 이김won勝ち |
| 2022Q2 | 20.2% | 15.8% | 20.4% | +4.44%ppp%pt | +4.65%ppp%pt | 이김won勝ち |
| 2022Q3 | 17.2% | 12.2% | 15.8% | +4.95%ppp%pt | +3.56%ppp%pt | 짐lost負け |
| 2022Q4 | 14.0% | 6.9% | 12.2% | +7.10%ppp%pt | +5.27%ppp%pt | 짐lost負け |
| 2023Q1 | 10.9% | 7.6% | 6.9% | +3.29%ppp%pt | -0.62%ppp%pt | 짐lost負け |
| 2023Q2 | 10.3% | 6.8% | 7.6% | +3.48%ppp%pt | +0.72%ppp%pt | 짐lost負け |
| 2023Q3 | 8.5% | 5.6% | 6.8% | +2.93%ppp%pt | +1.25%ppp%pt | 짐lost負け |
| 2023Q4 | 9.0% | 2.4% | 5.6% | +6.63%ppp%pt | +3.17%ppp%pt | 짐lost負け |
| 2024Q1 | 5.3% | 4.7% | 2.4% | +0.54%ppp%pt | -2.29%ppp%pt | 이김won勝ち |
| 2024Q2 | 5.2% | 6.4% | 4.7% | -1.23%ppp%pt | -1.72%ppp%pt | 이김won勝ち |
| 2024Q3 | 4.2% | 3.6% | 6.4% | +0.67%ppp%pt | +2.87%ppp%pt | 이김won勝ち |
| 2024Q4 | 4.6% | 0.6% | 3.6% | +4.06%ppp%pt | +3.01%ppp%pt | 짐lost負け |
| 2025Q1 | 3.5% | 6.3% | 0.6% | -2.86%ppp%pt | -5.77%ppp%pt | 이김won勝ち |
| 2025Q2 | 5.9% | 3.7% | 6.3% | +2.21%ppp%pt | +2.64%ppp%pt | 이김won勝ち |
| 2025Q3 | 5.4% | 5.1% | 3.7% | +0.26%ppp%pt | -1.46%ppp%pt | 이김won勝ち |
| 2025Q4 | 6.6% | 0.1% | 5.1% | +6.45%ppp%pt | +5.04%ppp%pt | 짐lost負け |
| 2026Q1 | 3.8% | 3.3% | 0.1% | +0.46%ppp%pt | -3.24%ppp%pt | 이김won勝ち |
| 2026Q2 | 11.0% | 14.9% | 3.3% | -3.98%ppp%pt | -11.61%ppp%pt | 이김won勝ち |
| 열린 Fcst · 분기Open Fcst · quarter未決着のFcst · 四半期 | 첫 발행First issued初回発行 | 첫 값First value初回値 | 마지막 발행Latest issued最終発行 | 마지막 값Latest value最終値 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | ± | 실제Actual実績 | 상태Status状態 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-10-22 | 10.5% | 2026-10-22 | 10.5% | 14.9% | 3.8%ppp%pt | 대기 · 마감 2026-11-14pending · due 2026-11-14待機 · 期限 2026-11-14 | 열림open未決着 |
| 2026Q4 | 2026-10-22 | 10.1% | 2026-10-23 (2회) (2 issues)(2回) | 10.0% | 14.9% | 3.8%ppp%pt | 대기 · 마감 2027-03-31pending · due 2027-03-31待機 · 期限 2027-03-31 | 열림open未決着 |
| 2027Q1 | 2026-10-22 | 9.0% | 2026-10-23 (2회) (2 issues)(2回) | 9.0% | 14.9% | 3.8%ppp%pt | 대기 · 마감 2027-05-15pending · due 2027-05-15待機 · 期限 2027-05-15 | 열림open未決着 |
| 2027Q2 | 2026-10-22 | 8.3% | 2026-10-23 (2회) (2 issues)(2回) | 8.3% | 14.9% | 3.8%ppp%pt | 대기 · 마감 2027-08-14pending · due 2027-08-14待機 · 期限 2027-08-14 | 열림open未決着 |
| 2027Q3 | 2026-10-22 | 7.9% | 2026-10-23 (2회) (2 issues)(2回) | 7.9% | 14.9% | 3.8%ppp%pt | 대기 · 마감 2027-11-14pending · due 2027-11-14待機 · 期限 2027-11-14 | 열림open未決着 |
| 2027Q4 | 2026-10-22 | 7.7% | 2026-10-23 (2회) (2 issues)(2回) | 7.8% | 14.9% | 3.8%ppp%pt | 대기 · 마감 2028-03-30pending · due 2028-03-30待機 · 期限 2028-03-30 | 열림open未決着 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
KPX케미칼 분기 영업이익률KPX Chemical quarterly operating marginKPX Chemical 四半期営業利益率 기준선 이김beats the baseline基準線に勝利
%ppp%pt · Data as of 2026Q2 · Created 2026-11-01드라이버: 관세청 제품·원료 단가 스프레드 + 브렌트 다리. 전진 검증 30분기 — 평균 |오차| 1.89%p vs 직전 분기 유지 1.92%p · 이긴 분기 19/30 · 우연으로 그만큼 이길 확률 0.10. 판정: 기준선보다 낫다(과반·평균 모두). 자세한 모델은 그 페이지에.Driver: customs product/raw-material unit prices with a Brent bridge (C2). Forward test over 30 quarters — mean |error| 1.89pp vs 1.92pp for the previous quarter carried forward · quarters won 19/30 · probability of winning that many by chance 0.10. Verdict: better than the baseline (on both the majority and the mean). The full model is on its page.ドライバー: 関税庁の製品・原料単価スプレッド + ブレントのブリッジ。フォワードテスト30四半期 — 平均|誤差| 1.89%pt(前四半期据え置きは1.92%pt)· 勝った四半期 19/30 · 偶然でそれだけ勝つ確率 0.10。判定: 基準線より良い(過半・平均の両方)。モデルの詳細はそのページに。
| 분기Quarter四半期 | 예측Forecast予測 | 실제Actual実績 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | 모델 오차Model errorモデル誤差 | 기준선 오차Baseline error基準線誤差 | 판정Verdict判定 |
|---|---|---|---|---|---|---|
| 2019Q1 | 5.4% | 4.2% | 4.1% | +1.14%ppp%pt | -0.18%ppp%pt | 짐lost負け |
| 2019Q2 | 4.9% | 6.3% | 4.2% | -1.34%ppp%pt | -2.03%ppp%pt | 이김won勝ち |
| 2019Q3 | 5.5% | 7.5% | 6.3% | -2.03%ppp%pt | -1.23%ppp%pt | 짐lost負け |
| 2019Q4 | 6.9% | 7.1% | 7.5% | -0.20%ppp%pt | +0.38%ppp%pt | 이김won勝ち |
| 2020Q1 | 6.4% | 7.0% | 7.1% | -0.57%ppp%pt | +0.13%ppp%pt | 짐lost負け |
| 2020Q2 | 1.1% | 7.0% | 7.0% | -5.82%ppp%pt | +0.03%ppp%pt | 짐lost負け |
| 2020Q3 | 5.4% | 7.8% | 7.0% | -2.40%ppp%pt | -0.83%ppp%pt | 짐lost負け |
| 2020Q4 | 6.6% | 11.6% | 7.8% | -4.94%ppp%pt | -3.76%ppp%pt | 짐lost負け |
| 2021Q1 | 8.7% | 6.4% | 11.6% | +2.36%ppp%pt | +5.20%ppp%pt | 이김won勝ち |
| 2021Q2 | 6.2% | 4.7% | 6.4% | +1.51%ppp%pt | +1.69%ppp%pt | 이김won勝ち |
| 2021Q3 | 5.2% | 2.8% | 4.7% | +2.39%ppp%pt | +1.87%ppp%pt | 짐lost負け |
| 2021Q4 | 4.3% | 3.9% | 2.8% | +0.38%ppp%pt | -1.11%ppp%pt | 이김won勝ち |
| 2022Q1 | 2.6% | 4.9% | 3.9% | -2.30%ppp%pt | -1.02%ppp%pt | 짐lost負け |
| 2022Q2 | 6.5% | 5.7% | 4.9% | +0.80%ppp%pt | -0.75%ppp%pt | 짐lost負け |
| 2022Q3 | 5.7% | 3.8% | 5.7% | +1.85%ppp%pt | +1.87%ppp%pt | 이김won勝ち |
| 2022Q4 | 4.6% | 4.4% | 3.8% | +0.20%ppp%pt | -0.62%ppp%pt | 이김won勝ち |
| 2023Q1 | 4.9% | 5.8% | 4.4% | -0.85%ppp%pt | -1.32%ppp%pt | 이김won勝ち |
| 2023Q2 | 5.7% | 4.5% | 5.8% | +1.16%ppp%pt | +1.22%ppp%pt | 이김won勝ち |
| 2023Q3 | 5.0% | 8.0% | 4.5% | -2.99%ppp%pt | -3.46%ppp%pt | 이김won勝ち |
| 2023Q4 | 6.7% | 7.3% | 8.0% | -0.58%ppp%pt | +0.72%ppp%pt | 이김won勝ち |
| 2024Q1 | 6.4% | 6.8% | 7.3% | -0.37%ppp%pt | +0.49%ppp%pt | 이김won勝ち |
| 2024Q2 | 6.2% | 5.1% | 6.8% | +1.08%ppp%pt | +1.69%ppp%pt | 이김won勝ち |
| 2024Q3 | 5.3% | 5.2% | 5.1% | +0.10%ppp%pt | -0.12%ppp%pt | 이김won勝ち |
| 2024Q4 | 5.4% | 3.0% | 5.2% | +2.44%ppp%pt | +2.24%ppp%pt | 짐lost負け |
| 2025Q1 | 4.3% | 4.7% | 3.0% | -0.38%ppp%pt | -1.69%ppp%pt | 이김won勝ち |
| 2025Q2 | 5.1% | 4.6% | 4.7% | +0.46%ppp%pt | +0.06%ppp%pt | 짐lost負け |
| 2025Q3 | 5.0% | 5.6% | 4.6% | -0.58%ppp%pt | -0.97%ppp%pt | 이김won勝ち |
| 2025Q4 | 5.5% | -2.9% | 5.6% | +8.41%ppp%pt | +8.47%ppp%pt | 이김won勝ち |
| 2026Q1 | 1.2% | 2.8% | -2.9% | -1.55%ppp%pt | -5.64%ppp%pt | 이김won勝ち |
| 2026Q2 | 3.9% | 9.4% | 2.8% | -5.46%ppp%pt | -6.65%ppp%pt | 이김won勝ち |
| 열린 Fcst · 분기Open Fcst · quarter未決着のFcst · 四半期 | 첫 발행First issued初回発行 | 첫 값First value初回値 | 마지막 발행Latest issued最終発行 | 마지막 값Latest value最終値 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | ± | 실제Actual実績 | 상태Status状態 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-10-22 | 7.4% | 2026-10-22 | 7.4% | 9.4% | 1.9%ppp%pt | 대기 · 마감 2026-11-14pending · due 2026-11-14待機 · 期限 2026-11-14 | 열림open未決着 |
| 2026Q4 | 2026-10-22 | 6.4% | 2026-10-22 | 6.4% | 9.4% | 1.9%ppp%pt | 대기 · 마감 2027-03-31pending · due 2027-03-31待機 · 期限 2027-03-31 | 열림open未決着 |
| 2027Q1 | 2026-10-22 | 5.9% | 2026-10-22 | 5.9% | 9.4% | 1.9%ppp%pt | 대기 · 마감 2027-05-15pending · due 2027-05-15待機 · 期限 2027-05-15 | 열림open未決着 |
| 2027Q2 | 2026-10-22 | 5.6% | 2026-10-22 | 5.6% | 9.4% | 1.9%ppp%pt | 대기 · 마감 2027-08-14pending · due 2027-08-14待機 · 期限 2027-08-14 | 열림open未決着 |
| 2027Q3 | 2026-10-22 | 5.5% | 2026-10-22 | 5.5% | 9.4% | 1.9%ppp%pt | 대기 · 마감 2027-11-14pending · due 2027-11-14待機 · 期限 2027-11-14 | 열림open未決着 |
| 2027Q4 | 2026-10-22 | 5.4% | 2026-10-22 | 5.4% | 9.4% | 1.9%ppp%pt | 대기 · 마감 2028-03-30pending · due 2028-03-30待機 · 期限 2028-03-30 | 열림open未決着 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
코스모신소재 분기 영업이익률Cosmo Advanced Materials & Technology quarterly operating marginCosmo Advanced Materials & Technology 四半期営業利益率 기준선 이김beats the baseline基準線に勝利
%ppp%pt · Data as of 2026Q2 · Created 2026-11-01드라이버: 관세청 제품·원료 단가 스프레드 + 브렌트 다리. 전진 검증 6분기 — 평균 |오차| 1.05%p vs 직전 분기 유지 1.25%p · 이긴 분기 6/6 · 우연으로 그만큼 이길 확률 0.02. 판정: 기준선보다 낫다(과반·평균 모두). 자세한 모델은 그 페이지에.Driver: customs product/raw-material unit prices with a Brent bridge (M3). Forward test over 6 quarters — mean |error| 1.05pp vs 1.25pp for the previous quarter carried forward · quarters won 6/6 · probability of winning that many by chance 0.02. Verdict: better than the baseline (on both the majority and the mean). The full model is on its page.ドライバー: 関税庁の製品・原料単価スプレッド + ブレントのブリッジ。フォワードテスト6四半期 — 平均|誤差| 1.05%pt(前四半期据え置きは1.25%pt)· 勝った四半期 6/6 · 偶然でそれだけ勝つ確率 0.02。判定: 基準線より良い(過半・平均の両方)。モデルの詳細はそのページに。
| 분기Quarter四半期 | 예측Forecast予測 | 실제Actual実績 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | 모델 오차Model errorモデル誤差 | 기준선 오차Baseline error基準線誤差 | 판정Verdict判定 |
|---|---|---|---|---|---|---|
| 2025Q1 | 4.1% | 0.9% | 4.4% | +3.17%ppp%pt | +3.46%ppp%pt | 이김won勝ち |
| 2025Q2 | 0.8% | 0.4% | 0.9% | +0.39%ppp%pt | +0.48%ppp%pt | 이김won勝ち |
| 2025Q3 | 0.3% | 0.1% | 0.4% | +0.13%ppp%pt | +0.31%ppp%pt | 이김won勝ち |
| 2025Q4 | 0.2% | 0.6% | 0.1% | -0.42%ppp%pt | -0.45%ppp%pt | 이김won勝ち |
| 2026Q1 | 0.7% | 0.7% | 0.6% | +0.01%ppp%pt | -0.14%ppp%pt | 이김won勝ち |
| 2026Q2 | 1.2% | 3.4% | 0.7% | -2.18%ppp%pt | -2.67%ppp%pt | 이김won勝ち |
| 열린 Fcst · 분기Open Fcst · quarter未決着のFcst · 四半期 | 첫 발행First issued初回発行 | 첫 값First value初回値 | 마지막 발행Latest issued最終発行 | 마지막 값Latest value最終値 | 직전 분기 유지Previous quarter carried forward前四半期据え置き | ± | 실제Actual実績 | 상태Status状態 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-10-22 | 3.9% | 2026-10-22 | 3.9% | 3.4% | 1.1%ppp%pt | 대기 · 마감 2026-11-14pending · due 2026-11-14待機 · 期限 2026-11-14 | 열림open未決着 |
| 2026Q4 | 2026-10-22 | 3.9% | 2026-10-22 | 3.9% | 3.4% | 1.1%ppp%pt | 대기 · 마감 2027-03-31pending · due 2027-03-31待機 · 期限 2027-03-31 | 열림open未決着 |
| 2027Q1 | 2026-10-22 | 3.9% | 2026-10-22 | 3.9% | 3.4% | 1.1%ppp%pt | 대기 · 마감 2027-05-15pending · due 2027-05-15待機 · 期限 2027-05-15 | 열림open未決着 |
| 2027Q2 | 2026-10-22 | 3.9% | 2026-10-22 | 3.9% | 3.4% | 1.1%ppp%pt | 대기 · 마감 2027-08-14pending · due 2027-08-14待機 · 期限 2027-08-14 | 열림open未決着 |
| 2027Q3 | 2026-10-22 | 3.9% | 2026-10-22 | 3.9% | 3.4% | 1.1%ppp%pt | 대기 · 마감 2027-11-14pending · due 2027-11-14待機 · 期限 2027-11-14 | 열림open未決着 |
| 2027Q4 | 2026-10-22 | 3.9% | 2026-10-22 | 3.9% | 3.4% | 1.1%ppp%pt | 대기 · 마감 2028-03-30pending · due 2028-03-30待機 · 期限 2028-03-30 | 열림open未決着 |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
대기 — 자체 채점 블록이 채워지면 합류Pending — joins once its own scoring block fills待機 — 独自の採点ブロックが埋まれば合流
Created 2026-11-01| 모델Modelモデル | 종목 수Companies銘柄数 | 마지막 실제Latest actual最新実績 | 다음 채점 분기Next quarter scored次の採点四半期 | 첫 채점(법정 마감)First scoring (statutory deadline)初回採点(法定期限) | 채점 끝남Scored採点済み | 메모Noteメモ |
|---|---|---|---|---|---|---|
| 선행 P/E 나우캐스트(수출 연동 분기 이익)Forward P/E nowcast (export-linked quarterly earnings)予想PERナウキャスト(輸出連動の四半期利益) | 127 | 2026Q2 | 2026Q3 | 2026-11-14 | 0 | 회사마다 walk-forward 로 드라이버를 고른다 — 3Q26 분기보고서가 모이면(법정 마감 2026-11-14) 자체 채점 블록이 채워지고 여기로 옮긴다Each company’s driver is chosen walk-forward — once the 3Q26 quarterly reports are in (statutory deadline 2026-11-14), its own scoring block fills and it moves here会社ごとにwalk-forwardでドライバーを選ぶ — 3Q26の四半期報告書が揃えば(法定期限 2026-11-14)独自の採点ブロックが埋まり、ここへ移す |
Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage
천장 — 이 페이지가 말할 수 없는 것Ceilings — what this page cannot say限界 — このページが言えないこと
- 표본이 작다. 검증 분기가 6~30개라 '이겼다'가 우연일 확률이 모델마다 적혀 있다 — p 가 0.05 를 넘으면 기준선과 같다고 읽는다.The samples are small. With 6–30 test quarters, the probability that a 'win' is chance is given for each model — if p is above 0.05, read it as no different from the baseline.標本が小さい。検証四半期が6〜30個のため、「勝った」が偶然である確率をモデルごとに記している — pが0.05を超えれば基準線と同じと読む。
- 컨센서스가 없다. 시장 기대와 견주지 못하고 직전 분기 유지와만 견준다.There is no consensus. Forecasts are not compared with market expectations, only with the previous quarter carried forward.コンセンサスがない。市場予想とは比べられず、前四半期据え置きとだけ比べる。
- 오차는 모델이 낸 값 그대로다. 발행 뒤 바뀐 값은 새 줄로 쌓이고 첫 값은 지워지지 않는다.Errors use the values exactly as the model issued them. Values changed after issue are stacked as new rows, and the first value is never deleted.誤差はモデルが出した値そのままで測る。発行後に変わった値は新しい行として積み上がり、初回値は消されない。